Full Text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

3D printing technologies enable medicine customization adapted to patients’ needs. There are several 3D printing techniques available, but majority of dosage forms and medical devices are printed using nozzle-based extrusion, laser-writing systems, and powder binder jetting. 3D printing has been demonstrated for a broad range of applications in development and targeting solid, semi-solid, and locally applied or implanted medicines. 3D-printed solid dosage forms allow the combination of one or more drugs within the same solid dosage form to improve patient compliance, facilitate deglutition, tailor the release profile, or fabricate new medicines for which no dosage form is available. Sustained-release 3D-printed implants, stents, and medical devices have been used mainly for joint replacement therapies, medical prostheses, and cardiovascular applications. Locally applied medicines, such as wound dressing, microneedles, and medicated contact lenses, have also been manufactured using 3D printing techniques. The challenge is to select the 3D printing technique most suitable for each application and the type of pharmaceutical ink that should be developed that possesses the required physicochemical and biological performance. The integration of biopharmaceuticals and nanotechnology-based drugs along with 3D printing (“nanoprinting”) brings printed personalized nanomedicines within the most innovative perspectives for the coming years. Continuous manufacturing through the use of 3D-printed microfluidic chips facilitates their translation into clinical practice.

Details

Title
3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals
Author
Serrano, Dolores R 1   VIAFID ORCID Logo  ; Aytug Kara 2   VIAFID ORCID Logo  ; Yuste, Iván 2 ; Luciano, Francis C 2 ; Ongoren, Baris 2 ; Anaya, Brayan J 2   VIAFID ORCID Logo  ; Molina, Gracia 2 ; Diez, Laura 2 ; Ramirez, Bianca I 2   VIAFID ORCID Logo  ; Ramirez, Irving O 2 ; Sánchez-Guirales, Sergio A 2   VIAFID ORCID Logo  ; Fernández-García, Raquel 2 ; Bautista, Liliana 2 ; Ruiz, Helga K 3   VIAFID ORCID Logo  ; Lalatsa, Aikaterini 4   VIAFID ORCID Logo 

 Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Instituto Universitario de Farmacia Industrial, Universidad Complutense de Madrid, 28040 Madrid, Spain 
 Department of Pharmaceutics and Food Science, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain 
 Department of Physical Chemistry, Complutense University of Madrid, 28040 Madrid, Spain 
 Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK; CRUK Formulation Unit, School of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK 
First page
313
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2779536289
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.